VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 2.18 Million USD | -16.41% |
| 2021 | 2.6 Million USD | -43.95% |
| 2020 | 4.65 Million USD | 20.18% |
| 2019 | 3.87 Million USD | 0.0% |
| 2014 | 3.86 Million USD | 20.36% |
| 2013 | 3.2 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2006 | 2 Million USD | -8.03% |
| 2005 | 2.18 Million USD | 12.36% |
| 2004 | 1.94 Million USD | -75.68% |
| 2003 | 7.99 Million USD | 201.75% |
| 2002 | 2.64 Million USD | -71.41% |
| 2001 | 9.26 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 2.15 Million USD | -1.38% |
| 2023 Q3 | 2.11 Million USD | -3.86% |
| 2023 Q2 | 2.19 Million USD | 2.06% |
| 2022 FY | 2.18 Million USD | -16.41% |
| 2022 Q4 | 2.18 Million USD | 6.88% |
| 2022 Q3 | 2.04 Million USD | 0.0% |
| 2021 Q3 | 3.08 Million USD | 0.0% |
| 2021 FY | 2.6 Million USD | -43.95% |
| 2020 FY | 4.65 Million USD | 20.18% |
| 2019 FY | 3.87 Million USD | 0.0% |
| 2015 Q1 | 4.24 Million USD | 10.04% |
| 2015 Q3 | 3.38 Million USD | -17.27% |
| 2015 Q2 | 4.09 Million USD | -3.72% |
| 2014 Q4 | 3.86 Million USD | 4.41% |
| 2014 FY | 3.86 Million USD | 20.36% |
| 2014 Q1 | 2.96 Million USD | -7.5% |
| 2014 Q2 | 3.26 Million USD | 10.08% |
| 2014 Q3 | 3.69 Million USD | 13.21% |
| 2013 Q4 | 3.2 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 3.2 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2007 Q3 | 89.82 Thousand USD | -94.09% |
| 2007 Q2 | 1.51 Million USD | -57.05% |
| 2007 Q1 | 3.53 Million USD | 76.1% |
| 2006 Q2 | 5.6 Million USD | 8.73% |
| 2006 FY | 2 Million USD | -8.03% |
| 2006 Q1 | 5.15 Million USD | 136.02% |
| 2006 Q4 | 2 Million USD | -63.05% |
| 2006 Q3 | 5.43 Million USD | -3.0% |
| 2005 Q4 | 2.18 Million USD | 2.37% |
| 2005 Q3 | 2.13 Million USD | 9.75% |
| 2005 Q2 | 1.94 Million USD | 0.0% |
| 2005 Q1 | 1.94 Million USD | 0.0% |
| 2005 FY | 2.18 Million USD | 12.36% |
| 2004 FY | 1.94 Million USD | -75.68% |
| 2004 Q4 | 1.94 Million USD | 59.63% |
| 2004 Q3 | 1.21 Million USD | -83.82% |
| 2004 Q2 | 7.52 Million USD | -4.93% |
| 2004 Q1 | 7.91 Million USD | -0.94% |
| 2003 Q2 | 8.05 Million USD | 244.62% |
| 2003 FY | 7.99 Million USD | 201.75% |
| 2003 Q4 | 7.99 Million USD | -4.83% |
| 2003 Q3 | 8.39 Million USD | 4.25% |
| 2003 Q1 | 2.33 Million USD | -11.75% |
| 2002 Q3 | 6.89 Million USD | -8.45% |
| 2002 Q2 | 7.53 Million USD | 1.69% |
| 2002 Q1 | 7.4 Million USD | -19.1% |
| 2002 FY | 2.64 Million USD | -71.41% |
| 2002 Q4 | 2.64 Million USD | -61.59% |
| 2001 Q2 | - USD | -100.0% |
| 2001 FY | 9.26 Million USD | 0.0% |
| 2001 Q3 | 250.92 Thousand USD | 0.0% |
| 2001 Q1 | 229.98 Thousand USD | -5.14% |
| 2001 Q4 | 9.15 Million USD | 3549.0% |
| 2000 Q4 | 242.44 Thousand USD | 1.56% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | 238.71 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 94.707% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 47.091% |
| SQZ Biotechnologies Company | 27.47 Million USD | 92.061% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 94.972% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 92.673% |
| Mesoblast Limited | 118.7 Million USD | 98.163% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -129.987% |
| Genus plc | 233.1 Million USD | 99.064% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 25.576% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -62.32% |
| Marizyme, Inc. | 18.71 Million USD | 88.348% |
| ContraFect Corporation | 2.88 Million USD | 24.301% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -190.787% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1509.675% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -50.79% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 6.236% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 61.457% |
| MultiCell Technologies, Inc. | 202.58 USD | -1076462.346% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 96.206% |
| EV Biologics, Inc. | 1.49 Million USD | -45.904% |
| Q BioMed Inc. | 4.1 Million USD | 46.936% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 93.411% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -246.132% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -77.546% |
| Biomind Labs Inc. | 735.54 Thousand USD | -196.502% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.729% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 83.22% |
| Skye Bioscience, Inc. | 4.61 Million USD | 52.746% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -145.579% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1441.076% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 62.854% |
| IMV Inc. | 28.88 Million USD | 92.449% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -8379.723% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 3.431% |
| GB Sciences, Inc. | 1.75 Million USD | -23.964% |
| Alpha Cognition Inc. | 1.22 Million USD | -78.708% |
| HST Global, Inc. | 98.31 Thousand USD | -2118.188% |
| CSL Limited | 12.18 Billion USD | 99.982% |
| Halberd Corporation | 150 Thousand USD | -1353.933% |
| Enzolytics Inc. | 996.33 Thousand USD | -118.892% |
| Resverlogix Corp. | 6.49 Million USD | 66.401% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -356.733% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -753.274% |
| argenx SE | 20 Million USD | 89.096% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 95.213% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 19.485% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -21229.095% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.478% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -987.102% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 9.043% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -851.149% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 96.776% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 27.933% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -506.294% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 89.271% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1367.098% |
| BioStem Technologies, Inc. | 4.71 Million USD | 53.71% |
| ONE Bio Corp. | 19.71 Million USD | 88.938% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -771.725% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -776.849% |
| Agentix Corp. | 50 Thousand USD | -4261.8% |
| LadRx Corporation | 33.6 Thousand USD | -6389.615% |
| Cell Source, Inc. | 9.25 Million USD | 76.433% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -188.401% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -188.401% |
| NovAccess Global Inc. | 2.19 Million USD | 0.863% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 69.165% |
| Itoco Inc. | 228.37 Thousand USD | -854.956% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -933.724% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 56.233% |
| Kadimastem Ltd | 891.22 Thousand USD | -144.708% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -442.716% |
| CytoDyn Inc. | 30.07 Million USD | 92.749% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -350.335% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -519.843% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 72.111% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1680.327% |
| Rebus Holdings, Inc. | 310 Thousand USD | -603.516% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 53.944% |
| International Stem Cell Corporation | 4.17 Million USD | 47.8% |
| Bioxytran, Inc. | 1.92 Million USD | -13.294% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3394.304% |
| Cardax, Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 73.775% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 74.596% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -40.208% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -713.769% |
| Neutra Corp. | 54.15 Thousand USD | -3927.07% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -19.175% |
| PureTech Health plc | 25.51 Million USD | 91.451% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -78.145% |
| IXICO plc | 472.02 Thousand USD | -362.033% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 85.931% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.497% |
| CSL Limited | 12.18 Billion USD | 99.982% |
| Cellectis S.A. | 92.77 Million USD | 97.649% |